Medi One Pharma Labs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth -32.12%
- Profit Growth -150.46%
- Ebitda -336.92%
- Net Worth -80.12%
- Total Assets 65.19%
About Medi One Pharma Labs
Medi One Pharma Labs Private Limited (MOPLPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 November 2019 (Five years and three months 12 days old ). Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Girajala Rajasekhar and Sree Girajala serve as directors at the Company.
Company Details
-
Location
Tiruvallur, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51909TN2019PTC132429
-
Company No.
132429
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Nov 2019
-
Date of AGM
16 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Medi One Pharma Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girajala Rajasekhar
|
Managing Director | 06-Nov-2019 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sree Girajala
|
Director | 01-Feb-2021 | Current |
Financial Performance of Medi One Pharma Labs.
Medi One Pharma Labs Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 32.12% decrease. The company also saw a substantial fall in profitability, with a 150.46% decrease in profit. The company's net worth observed a substantial decline by a decrease of 80.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medi One Pharma Labs?
In 2021, Medi One Pharma Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Saccharon Excipients Private LimitedGirajala Rajasekhar and Sree Girajala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medi One Pharma Labs?
Unlock and access historical data on people associated with Medi One Pharma Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medi One Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medi One Pharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
